



## EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Aug 03, 2022

*Company to host conference call and webcast on Thursday, August 25<sup>th</sup> at 8:30 am EDT*

**LYON, France, August 3, 2022** - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30<sup>th</sup> after the markets close on Wednesday, August 24<sup>th</sup>, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, August 25<sup>th</sup>, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

### **Conference Call & Webcast**

#### **Thursday, August 25<sup>th</sup> @ 8:30am Eastern Time**

Domestic: 877-451-6152

International: 201-389-0879

Passcode: 13731177

Webcast: [https://viaid.webcasts.com/starthere.jsp?ei=1558239&tp\\_key=295933838c](https://viaid.webcasts.com/starthere.jsp?ei=1558239&tp_key=295933838c)

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, and [us.hifu-prostate.com](http://us.hifu-prostate.com).

### **Company contact:**

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 50

[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### **Investor Contact**

John Fraunces

LifeSci Advisors, LLC

212-915-2568

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)